Why Should You Use LOINC Codes For SDTM?
September 16, 2024 In this blog, we take a detailed look at LOINC Codes and…
CertaraSeptember 16, 2024
The SDTM Mapping Process Simplified
SDTM mapping can be one of the most challenging programming problems in a clinical trial…
CertaraSeptember 16, 2024
What Are SDTM Supplemental Qualifiers?
A detailed look at data that exists out with SDTM variables, known as SDTM supplemental…
CertaraSeptember 16, 2024
From Development to Patient Impact: Biohaven’s Nurtec™ Success Story
To learn more about Biohaven's success story, read our case study. Read the case study
CertaraSeptember 13, 2024
4 Ways That Mechanistic Modeling Accelerates Bispecific (and Multispecific) Antibody Drug Development
With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…
CertaraSeptember 12, 2024
Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report
Check out this article in Fierce Pharma to learn how Certara's US Market Access team…
CertaraSeptember 11, 2024
Certara Strategic Early Development Solutions
A comprehensive guide to optimizing early development strategies.
CertaraSeptember 9, 2024
Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)
Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…
CertaraSeptember 9, 2024
